Afamelanotide: what the studies show

Adults with EPP

Afamelanotide is the active ingredient in Scenesse. FDA approval concerns adults with a history of phototoxic reactions from erythropoietic protoporphyria, or EPP. The intended outcome is more light exposure without pain. This indication does not include cosmetic tanning.

Two randomized trials enrolled 94 US patients and 74 European patients. Afamelanotide increased cumulative pain-free direct-sunlight exposure over six and nine months, respectively. The exposure totals cover the study periods. They do not describe hours of protection from each implant. The trials also reported better quality of life.

The approved implant

Scenesse is a solid subcutaneous implant that a trained healthcare professional places every two months under the US label. It is not a conventional liquid injection. The evidence concerns this formulation and placement procedure. Afamelanotide and melanotan II are distinct molecules.

Limits and follow-up

Sun and light protection remain necessary during treatment. The label recommends full-body skin examinations twice yearly because pigment changes can affect existing moles and other lesions. The cited EPP trials do not answer whether afamelanotide prevents skin cancer or has benefits that outweigh the risks of cosmetic use.